Scientists diagnose Alzheimer's disease by blood test
Alzheimer's disease (AD) is characterized by a decline in cognitive function, memory loss, and in severe cases, language impairment, and ultimately the loss of independent living ability. According to estimates by Chinese Center for disease Control and Prevention, there are about 10 million AD patients in China, which will exceed 30 million by 2050, making it the country with the largest number of AD patients in the world. However, at present, Chinese residents have low awareness and attention to AD, and there are generally low diagnosis rates (especially early diagnosis) and low treatment rates.
Prof. Zhang Jing's team, from the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), collaborated with researchers at the University of Washington School of Medicine on the latest scientific research results based on plasma extracellular vesicles (EVs) in the early diagnosis of AD markers, "Blood Extracellular Vesicles Carrying Synaptic Function- and Brain-related Proteins as Potential Biomarkers for Alzheimer's disease." The study was published in Alzheimer's & Dementia.
This study developed a stable and rapid assay method for the quantitative determination of nervous system-derived EVs in plasma using nano-flow cytometry technology, and discovered novel peripheral blood central nerve system-derived EVs-related marker NMDAR2A to assess its diagnostic value for AD. This technology only requires a small amount of blood from the patient and checks the changes of several markers in the blood to assist in the diagnosis of AD.
Specifically, the study used innovative nano-flow detection technology to develop a stable and rapid assay method, and discovered a new type of marker that can be used to assist in the diagnosis of AD—peripheral blood nerve Source EVs-related marker NMDAR2A (Figure 1).
This method requires quantitative determination of central nervous system-derived L1CAM and NMDAR2A-positive EVs contained in plasma, and simultaneous detection of AD disease-related markers Aβ40, Aβ42, pTau231, and pTau396-related EVs. Through a large cohort study, this study found that compared with healthy people, the neurologically derived EVs and Aβ, pTau-related EVs in the peripheral blood of AD patients were significantly reduced. (Figure 2)
Compared with the traditional examination methods, the research published by Prof. Zhang Jing's team only needs to draw a small amount of blood from the subjects and check the changes of several markers in the blood to assist in the diagnosis of AD, which can replace the traditional CSF biomarkers. Therefore, it can solve the problems of low acceptance of CSF acquisition and high cost of corresponding imaging examinations in clinical work, realize rapid and accurate diagnosis of AD, and further it can be used for early screening of AD in the elderly. The new diagnosis and treatment method has great clinical practice and public health value, and provides new research ideas and directions for the early diagnosis of AD.